The biggest challenge in CSP is to be able to rank the thermodynamic stability of the 1 possible crystal structures accurately enough, given that the energy difference between 2 known polymorphs is typically around a kJ/mol, though it can be up to 8 kJ/mol for 3 conformational polymorphs [8] . The tiny energy differences between polymorphs can 4 sometimes be measured by the heat of transformation or by the difference in their heats of 5 fusion. The energy evaluation challenge is closely related to the problem of sufficient 6 accuracy in force-fields or electronic structure calculations for predicting protein structures 7 [31] or ligand binding energies in drug design [31, 32] . Since the lattice energy of benzene 8 has only recently been calculated to an absolute accuracy of less than 1 kJ/mol [33] , CSP 9 relies on effective cancellation of errors in the evaluation of the crystal energies. The more 10 successful methods in the Blind Test either used electronic structure calculations on the 11 isolated molecule conformations or on many hundreds of crystal structures. The Blind Tests 12 have shown that worthwhile crystal energy evaluations have to be based on the electronic 13 structure of the molecule and so scale very badly with the size of the molecule, the range of 14 conformations that could appear in the solid state, and the number of independent 15 molecules in the crystal structure (Box 1). The computational expense of the successful Blind 16
Test submissions for the larger systems was measured in hundreds of thousands of CPU 17 hours, corresponding to weeks to months of dedicated use of high performance computing 18
clusters [6] . 19
To date, crystal structure prediction studies have been performed on many model drug 20 compounds, and in cases such as aspirin, paracetamol, carbamazepine and 5-fluorouracil, 21
have anticipated the discovery of new polymorphs [34] . After the 2 nd Blind Test, two 22 additional polymorphs of the sulfonamide (VI) were found, and the more accurate ranking 23 by DFT-D showed that the known forms were the three lowest energy structures found [35] 24 in a search by the GRACE code [36] . Further examples of combined CSP and experimental 1 studies leading to the few lowest energy structures being observed polymorphs include 2 creatine [37] and 4-aminoquinaldine [38] and its most stable form, a polymorph of 3 4-aminoquinaldine monohydrate, which proved very difficult to access experimentally for 4 kinetic reasons [39] . This leads to the current research debate as to whether and why some 5 structures may never be found, despite their apparent computed stability, or alternatively, 6
whether an experiment can be devised to cause the first nucleation of any 7 thermodynamically plausible structure [5, 40] . 8
Academic work contrasting the known polymorphism of small organic molecules with the 9 output of a CSP study has led to the concept of a computed crystal energy landscape [4] . 10 This is the set of computer-generated crystal structures which are thermodynamically 11 plausible as polymorphs. However, in most cases, there are considerably more structures on 12 the crystal energy landscape than known polymorphs [5] . Some of these structures are 13 artifacts of the approximations currently used in calculating the crystal energy landscape, 14 particularly the neglect of temperature and hence the molecular motion within the crystals, 15 which means that not all structures are free energy minima. Would How computed crystal energy landscapes help define pharmaceutical solid form 8
landscapes. 9
Industrial pharmaceutical scientists have closely monitored the development of CSP 10 methods and in particular, the CCDC Blind Tests. Reliable CSP would determine whether 11 their screening had missed the most stable solid form and further screening was warranted. 12
Alternatively, if the practically important forms had been found, resources would be saved 13
by not unnecessarily prolonging the search for forms. When XX in the 2010 Blind Test 14 (Figure 2 ) inspired two groups to algorithmic developments that successfully predicted its 15 structure [46] , it showed that CSP methods were starting to be able to tackle molecules 16 approaching the size and complexity of some molecules in development. We review the 17 subsequent published examples of CSP that have been done in conjunction with industrial 18 polymorph screening to show that the value of adding this computational technique 19 extends well beyond right-sizing solid form screens. 20
As this review will show, the uses of crystal energy landscapes established from the 21 experience with small organic molecules can equally well be applied to pharmaceutical 22 molecules. The evaluation of CSP is particularly useful on pharmaceuticals because of the 23 extent of polymorph screening that has usually been done. It also presents a greatnexcellent opportunity to look at crystallization issues of pharmaceuticals, how they play out 1
in industry and what CSP can contribute. Given that there is no statistical evidence that 2 increasing molecular size and flexibility significantly changes the tendency to polymorphism 3 were under development for sleep disorders. B5 readily and reliably crystallizes into just one 20 solid form containing the neutral molecule, whereas three neat polymorphs, two hydrates, 21 three alcohol solvates and an amorphous phase are known for DB7 (Figure 1) [48]. The 22 screening effort was roughly equivalent for B5 and DB7 with respect to the number of 23 experiments, but since B5 crystallized so readily, it was very difficult to avoid memory of theinput materialminute molecular clusters (nuclei) of the starting form being carried over into 1 thein crystallization experiments, whereas amorphous DB7 could be used. The reason for 2 the difference in number of solid forms of B5 and DB7 was not a difference in the energy 3 spectrum of the crystal energy landscape (Figure 1 ), but rather in the density and nature of 4 the low energy structures. B5 could pack densely with itself, with most low energy 5 structures having an internal hydrogen bond. In contrast, DB7 had no good way of packing 6 densely with itself, with the packing coefficients of predicted low energy structures lying in 7 the lower half of the commonly observed range (65-75%). The low energy structures for DB7 8 mainly had intermolecular hydrogen bonds forming a range of motifs, showing that crystal 9 packing can have a major effect on the potential hydrogen bonding. These examples follow 10 the general rule observed for small molecules, that both the crystal structure and energy 11 landscapes are very specific to the individual molecule, and even the smallest changes in the 12 API will usually result in different crystal structures and probably crystallization behavior. The question was raised as to whether sample to sample variability in the properties of 23 Form III was due to concomitant crystallization of two closely related polymorphs. Thecomputed crystal energy landscape found a match to its powder diffraction pattern in two 1 structures, differing only in the propionic acid conformation, allowing characterization of 2 this solid form as a single polymorph with variable sidechain disorder ) [48] . In this instance, 3 the combined use of experimental screening and CSP showed a disordered structure for 4
Form III was inevitable, helping to clarify the number of forms produced by the solid form 5 screening) [48] . 6
In contrast, olanzapine, marketed for the treatment of schizophrenia, generated a lot of 7 work contesting patent claims of "novel" polymorphs by generic companies prior to its 8 coming off patent in the USA in 2011. In many cases, the purported forms were known 9 mixtures of the concomitantly crystallizing metastable polymorphs, Forms II and III. The 10 structure of Form II was only determined in 2011, when a single crystal suitable for X-ray 11 could be picked out from a sample of olanzapine that had failed to co-crystallize with 12 nicotinamide [50] . A single crystal of Form III was not identified for X-ray structure analysis; 13 however, the crystal energy landscape included a structure that was a sufficient match to 14 the Form III powder pattern to show that it was a different stacking of the same molecular 15 layers as Form II [51] . This structural model rationalizes why Forms II and III crystallize 16 concomitantly, with it being practically impossible to generate phase pure samples. 17
The problems of differentiation between different polymorphs and degrees of disorder, and 18 the consequences for the quality control of crystal properties, is further exemplified by the 19 case of tazofelone. The original screening of racemic tazofelone had produced two 20 polymorphs [52], which were based on the same layer structure with different stackings in 21 the third dimension. Revisiting this compound to obtain good thermodynamic data for 22
calibrating the CSP study [53] unexpectedly produced an alternative stacking as a third 23 polymorph. Of particular concern for ensuring quality control over material properties wasthat the large single crystals of each polymorph varied in melting point. This triggered an 1 unusually detailed examination of the raw diffraction data to reveal evidence of significant 2 disorder. The crystal energy landscape had the most stable form as the global minimum, but 3
showed that there were other ways of stacking the layers that were so close in energy, that 4 stacking errors or different polymorphic domains (polytypes) even within single crystals 5
were probably unavoidable. 6
Determination of crystal structure when single crystals cannot be grown. 7
The examples surveyed thus far show how crystal structures are sometimes needed in order 8 to clarify experimental solid form landscapes. Structural information is also used to 9 rationalize and understand crystallization behaviors, and as interest in emerging in silico 10 approaches to drug product design continues to grow, structures will undoubtedly be 11 necessary inputs to the modeling and prediction of solid-state properties well into the 12 future. A further example of using CSP, this time in conjunction with a range of experimental 13 techniques to determine the crystal structure, is illustrated for AZD8329, an 11-HSD1 14 inhibitor investigated for use in the treatment of type 2 diabetes. AZD8329 showed 15 significant polymorphismcrystallizes in at least four neat polymorphs, with Form 4, one of 16 two forms considered to have superior properties for development, not having a crystal 17 structure determination. The structure was proposed [54] by comparing the experimental 18 proton solid state NMR spectrum with those calculated from CSP generated structures (Box 19 1) with both the cis and trans amide conformations. The proposed structure of Form 4 with 20 a cis amide was in excellent agreement with that independently determined from powder X-21 ray diffraction, with the advantage of NMR spectroscopy having located the carboxylic acid 22 proton position. 23
A related study attempted to use CSP to find structures for the anhydrous forms of the 1 antibiotic levofloxacin, using the commercial program Polymorph Predictor [55] . In the end, 2 a plausible model was proposed after using the crystal structures of six carboxylic acid salt 3 and hydrate forms to choose six likely ππ stacked dimer structures, which were optimized 4 by electronic structure methods and held rigid during the CSP search. This illustrates the use 5 of a limited approximate form of CSP to extrapolate from a marked structural preference 6 ("structural synthon") seen in other solid state forms of the API. 7
Why are some molecules prolific solvate formers? 8
Many pharmaceuticals are prolific solvate formers, with sulphathiazole having over 100 9 solvates reported [56] . This considerably complicates the solid form screening output. 10
Pharmaceutical solvates with solvents that would never be allowed anywhere in a 11 production process because of their toxicity, have to be considered in screening because 12 desolvation [57] is a sufficiently productive method of finding new forms and may be the 13 only route to a new polymorph. Conversely, all possible hydrates have to be extensively 14 studied and characterized because of the impossibility of rigorously excluding water from 15 the production processes. Solvates can include multiple solvents, sometimes in variable 16 ratios, and the distinction between surface absorbed water, stoichiometric and non-17 stoichiometric hydrates is both critical for process design and difficult to establish [49] . 18 Labile solvates, where the solvent readily leaves the crystal when it is removed from the 19 crystallizing solution are common. CSP generated structures with void spaces can be 20 stabilized by the inclusion of solvent molecules [58] . The nature of this stabilization, the 21 ease of removing the solvent, and ability of the molecule to rearrange into a dense 22 unsolvated form is extremely dependent on the specific structure, but could suggest a route 23 to a desirable high solubility, low density, and kinetically stable form. The extension of theprinciples of CSP on inclusion compound frameworks and porous molecular cages [59] to 1 pharmaceutical solids and solvates is yet in its infancy, as a quicker, more general route to 2 predicting solvate formation [60, 61] . For example, we need to progress beyond just 3 attributing the formation of solvates and hydrates of DB7 and none for B5 to the inability of 4 only DB7 to pack densely by itself (Figure 1) . 5
Olanzapine also illustrates how the inability of a molecule to pack well with itself can give 6 rise to a multitude of solid forms, with over 60 being found in the screen [51] . Many of these 7 had differing solvent mixtures between layers of olanzapine dimers, and the crystal energy 8 landscape showed that these layers do not stack particularly well to form an unsolvated 9 crystal. The separation of solvate motifs and polymorphs is more challenging for the Pfizer 10 Is the lack of observed polymorphs in a screen reliable? 21
The failure of experimental solid form screens to produce more than one crystal form may 22 be due to one form being much more stable or crystallizing much more rapidly than all 23
others. In such cases, CSP can uniquely show whether monomorphism is a product ofthermodynamics or crystallization kinetics. An example where alternative crystal structures 1 were calculated [67] to be only slightly less stable than the only readily crystallized form is 2 GSK269984B. In this case, the hypothetical polymorphs had intermolecular hydrogen 3 bonding compensating for adopting grossly different, higher energy conformations than the 4 observed more stable, internally hydrogen bonded conformation [67] . Further screening, 5 concentrating on solvents that would be likely to hydrogen bond to the API, produced some 6 metastable solvates with the expected intermolecular hydrogen bonding, but the same 7 gross conformation as in the neat form. Thus the question arises as to whether the fast 8 crystallization of GSK269984B into its most stable form could be relied upon to prevent the 9 crystallization of the alternative computer generated structures [67] , given that solution 10 NMR showed that a range of other conformations could exist in solution. In ritonavir, it was 11 the small solution population of the higher energy conformation that was found in the most 12 stable polymorph that rationalized its disastrous later appearance [68,69]. The key 13 difference for GSK269984B is that the higher energy conformers are calculated to give 14 metastable polymorphs. 15
Crizotinib was developed by Pfizer for the treatment of forms of lung cancer, and extensive 16 polymorph and hydrate screening similarly found only one crystalline form. A simple CSP 17 search, based on just four rigid, carefully selected conformers and the five most common 18 chiral space groups, showed that the known structure was significantly more stable than any 19 other generated, rationalizing the lack of polymorphs [24] . That the known structure not 20 only had the lowest energy conformation but also optimal intermolecular interactions was 21 confirmed by a CCDC solid form informatics "healthcheck" [70] . It is unusual that there are 22 no signs of alternative crystal forms in the screening and so the computational confirmation 23 that there is no compromise between conformation and intermolecular packing in thestructure, and that it has a uniquely favourable packing defining all three dimensions, 1 provides valuable reassurance. 2
Suggesting experiments to find new polymorphs 3
A polymorph that had been missed in extensive experimental screening of Roche's CETP 4 inhibitor, Dalcetrapib, has recently been found by crystallisation under pressure, an 5 experiment suggested by the CSP study [71] . The crystal energy landscape had two 6 structures very close in energy, but denser than the known stable form; which was the most 7 stable structure of all those generated in the search depending on the DFT-D method used. 8
The unknown structures were calculated to become more stable than the observed 9 polymorph with a modest increase in pressure. Figure 3 ) cannot be assumed to have the same crystallisation 5 behaviour as small, rigid molecules which can readily rearrange to the most stable form. The 6 molecule may not be able to pack densely with itself, and may not be able to change 7 conformation or hydrogen bonding sufficiently during crystallisation to readily achieve the 8 most stable structure. Polymorphs formed as desolvated solvates, or by chemical 9 transformation (such as proton exchange) once the molecules are already highly aggregated 10 may be very long-lived but far more metastable than small molecule polymorphs. Can the 11 most stable structure on the crystal energy landscape always be crystallised? There are 12 molecules that prove extremely difficult to crystallise at all, and so in these cases the first 13 form is likely to be the fastest to nucleate and grow, which is not necessarily the most 14 stable. Recent work on both a crystallographic dataset of diastereomers and chiral-racemic 15 pairs [78] , and many real and CSP generated crystal structures of mandelic acids [40] both 16 point to statistics of nucleation and growth causing the rarity of spontaneous resolution of 17 enantiomers by crystallization, and raise the possibility that the most stable computer 18 generated structure may be very unlikely to ever form. Some intensively studied, highly experimental work. There is still a long way to go until we understand the kinetics of 6 nucleation and growth sufficiently to be able to proceed from calculating a crystal energy 7 landscape to a reliable method of polymorph prediction. 8
Conclusion 9
We have reviewed a dozen case studies that have been published in the last few years since 10 it has become possible to perform CSP studies on small drug molecules which are being 11 screened in industry. The studies which that augment solid form screening show very 12 different behavior, from reliable crystallization into one solid form through to extensive 13 polymorphism, and the need for CSP to characterize forms and help rationalize and cope 14 with problematic crystallization behavior such as disorder. Each case is unique, just as every 15 polymorph screen is unique and the optimal design of each drug product is unique. The 16 computed crystal energy landscapes can provide the early warnings of where the issues in 17 further development of the drug product and processing will lie. Molecular-level insights will 18 help to us to reduce the experimental burden showing us the steps to the promised goal. 19
Computational crystal structure prediction is en route towards delivering on the two most 20 important industrial promises: lead experimentalists to new crystal forms and help decide 21 when it is safe to stop screening. As the ability to predict key properties, such as solubility or 22 mechanical properties from the crystal structure improves, the crystal energy landscape will 23 LY2806920 "B5" and LY2624803 "DB7" [48] , whose molecular structures are given in Figure  2 3. Left, the solid forms of the molecules and their interrelationships; right, the energies and 3 packing efficiencies of the computer generated structures, with every symbol denoting a 4 computer generated structure that is mechanically stable, according to the hydrogen 5 bonding motif in graph-set notation [89] . 
